NASDAQ : OTLK
Outlook Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.4935 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 120.14M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 114.23M |
| Enterprise Value | 121.41M |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 18, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 243.45M |
| Shares Outstanding | 243.45M |
| Shares Change (YoY) | +182.49% |
| Shares Change (QoQ) | +67.09% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 21.40% |
| Float | 176.57M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 4.14 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.81 |
| Quick Ratio | 0.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -210.62 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -143.17% |
| Return on Invested Capital (ROIC) | -1,253.84% |
| Return on Capital Employed (ROCE) | 2,230.60% |
| Weighted Average Cost of Capital (WACC) | 7.01% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.60M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | 0.24 |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.55M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -62.76% |
| 50-Day Moving Average | 0.60 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 36.22 |
| Average Volume (20 Days) | 3,861,696 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 32.59M |
| Short Previous Month | 31.90M |
| Short % of Shares Out | 13.39% |
| Short % of Float | 18.46% |
| Short Ratio (days to cover) | 6.98 |
Incomestatement
| Measure | Value |
|---|
| Revenue | -1.16M |
| Gross Profit | -2.28M |
| Operating Income | -55.64M |
| Pretax Income | -62.68M |
| Net Income | -61.12M |
| EBITDA | -55.53M |
| EBIT | -55.64M |
| Loss Per Share | -$0.75 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 11.24M |
| Total Debt | 18.43M |
| Net Cash | -7.19M |
| Net Cash Per Share | -$0.03 |
| Equity (Book Value) | -10.39M |
| Book Value Per Share | -0.06 |
| Working Capital | -5.51M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -56.15M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 104,019 |
| Net Borrowing | -2.33M |
| Free Cash Flow | -56.15M |
| FCF Per Share | -$0.23 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | 4,781.84% |
| Pretax Margin | 5,387.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -182.49% |
| Shareholder Yield | -182.49% |
| Earnings Yield | -159.41% |
| FCF Yield | -49.16% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.03 |
| Price Target Difference | 970.97% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 394.24% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 14, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -41.12 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |